These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 24217470)

  • 1. Treatment of advanced cutaneous squamous cell carcinomas with epidermal growth factor receptor inhibitors.
    Alter M; Satzger I; Mattern A; Kapp A; Gutzmer R
    Dermatology; 2013; 227(4):289-94. PubMed ID: 24217470
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
    Eder J; Simonitsch-Klupp I; Trautinger F
    Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An evolving paradigm for the workup and management of high-risk cutaneous squamous cell carcinoma.
    O'Bryan K; Sherman W; Niedt GW; Taback B; Manolidis S; Wang A; Ratner D
    J Am Acad Dermatol; 2013 Oct; 69(4):595-602.e1. PubMed ID: 23871719
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
    Jedlinski A; Ansell A; Johansson AC; Roberg K
    J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatal diffuse alveolar damage in two lung transplant patients treated with cetuximab.
    Leard LE; Cho BK; Jones KD; Hays SR; Tope WD; Golden JA; Hoopes CW
    J Heart Lung Transplant; 2007 Dec; 26(12):1340-4. PubMed ID: 18096489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Cohen EE
    J Clin Oncol; 2006 Jun; 24(17):2659-65. PubMed ID: 16763280
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update of cetuximab for non-melanoma skin cancer.
    Wollina U
    Expert Opin Biol Ther; 2014 Feb; 14(2):271-6. PubMed ID: 24387664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab in squamous cell carcinoma of the head and neck.
    Hitt R; Martín P; Hidalgo M
    Future Oncol; 2006 Aug; 2(4):449-57. PubMed ID: 16922611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rescue therapy with anti-programmed cell death protein 1 inhibitors of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in five cases.
    Borradori L; Sutton B; Shayesteh P; Daniels GA
    Br J Dermatol; 2016 Dec; 175(6):1382-1386. PubMed ID: 27059424
    [No Abstract]   [Full Text] [Related]  

  • 12. The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target.
    Gaffney DC; Soyer HP; Simpson F
    Australas J Dermatol; 2014 Feb; 55(1):24-34. PubMed ID: 23425099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of an EGFR blocker and a COX-2 inhibitor for the treatment of advanced cutaneous squamous cell carcinoma.
    Jalili A; Pinc A; Pieczkowski F; Karlhofer FM; Stingl G; Wagner SN
    J Dtsch Dermatol Ges; 2008 Dec; 6(12):1066-9. PubMed ID: 19138272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
    Saba NF; Khuri FR; Shin DM
    Oncology (Williston Park); 2006 Feb; 20(2):153-61; discussion 162, 166, 169 passim. PubMed ID: 16562649
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of recurrent squamous cell carcinoma of the skin with cetuximab.
    Bauman JE; Eaton KD; Martins RG
    Arch Dermatol; 2007 Jul; 143(7):889-92. PubMed ID: 17638733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR targeting drugs in the treatment of head and neck squamous cell carcinoma.
    Sundvall M; Karrila A; Nordberg J; Grénman R; Elenius K
    Expert Opin Emerg Drugs; 2010 Jun; 15(2):185-201. PubMed ID: 20415599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of cetuximab as an adjuvant agent to radiotherapy and surgery in recessive dystrophic epidermolysis bullosa with squamous cell carcinoma.
    Kim M; Li M; Intong LR; Tran K; Melbourne W; Marucci D; Bucci J; de Souza P; Mallesara G; Murrell DF
    Br J Dermatol; 2013 Jul; 169(1):208-10. PubMed ID: 23398414
    [No Abstract]   [Full Text] [Related]  

  • 18. Cutaneous squamous cell carcinoma responding serially to single-agent cetuximab.
    Suen JK; Bressler L; Shord SS; Warso M; Villano JL
    Anticancer Drugs; 2007 Aug; 18(7):827-9. PubMed ID: 17581306
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multi institutional phase II study of concomitant stereotactic reirradiation and cetuximab for recurrent head and neck cancer.
    Lartigau EF; Tresch E; Thariat J; Graff P; Coche-Dequeant B; Benezery K; Schiappacasse L; Degardin M; Bondiau PY; Peiffert D; Lefebvre JL; Lacornerie T; Kramar A
    Radiother Oncol; 2013 Nov; 109(2):281-5. PubMed ID: 24262821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms of the epidermal growth factor receptor (EGFR) and survival in patients with advanced cancer of the head and neck (HNSCC).
    Stoehlmacher-Williams J; Obermann L; Ehninger G; Goekkurt E
    Anticancer Res; 2012 Feb; 32(2):421-5. PubMed ID: 22287728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.